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Hypercalcemia is a relatively common clinical problem in both outpatient and inpatient settings. Primary pathophysiology is
the entry of calcium that exceeds its excretion into urine or deposition in bone into circulation. Among a wide array of causes
of hypercalcemia, hyperparathyroidism and malignancy are the most common, accounting for greater than 90 percent of cases.
Concordantly, there has been a resurgence of milk-alkali syndrome associated with the ingestion of large amounts of calcium and
absorbable alkali, making it the third leading cause of hypercalcemia (Beall and Scoﬁeld, 1995 and Picolos et al., 2005). This paper
centers on a case of over-the-counter calcium and alkali ingestion for acid reﬂux leading to milk alkali with concordant use of
thiazide diuretic for hypertension.
1.Introduction
Sippy, almost 100 years ago, developed a calcium-laden milk
and antacid regimen for the treatment of peptic ulcer disease
[1]. The rationale was to neutralize the hyperacidity that
was deemed responsible for peptic ulcer disease. The Sippy
regimen until the 1970s was used for the treatment of peptic
ulcer disease, a disorder that was predominant in middle-
aged men, when nonantacid treatment was ﬁrst introduced
[1, 2]. Sippy’s original recommendation consisted of the
hourly administration of milk and cream together with
what became known as the Sippy powders, which were 10
grains (1 grain = 65mg) each of heavily calcinated magnesia
and sodium bicarbonate, alternating with a powder that
contained 10 grains of bismuth subcarbonate and 20 to 30
grains of sodium bicarbonate [1].
Hardt and Rivers in 1923 gave a detailed description of
the toxicity that was associated with the antacid and milk
regimen [3]. The symptoms consisted of nausea, vomiting,
headache, dizziness, musculoskeletal pains, and weakness
followed by prostration. There was an associated elevation of
blood urea nitrogen (BUN) and serum creatinine, alkalosis,
and albuminuria. Cope in 1936 ﬁrst recognized hypercal-
cemia as a major feature of this toxicity [4]. He also showed
a rapid resolution of alkalosis and hypercalcemia after
cessation of treatment, but the recovery of renal function
wasmuchslower.Fundamentally,thediﬀerentiationofmilk-
alkali syndrome from primary hyperparathyroidism was
evident due to the absence of hypophosphatemia and the
resolutionofthehypercalcemiaoncetreatmentwithantacids
was stopped. Burnett et al. in 1949 described a chronic
variantofthemilk-alkalisyndromeinwhichrenalfailurewas
persistent and soft tissue calciﬁcations were extensive [5].
Punsar and Somer in 1963 classiﬁed milk-alkali syn-
drome into three diﬀerent types: acute, subacute (Cope’s
syndrome), and chronic (Burnett’s syndrome) toxicity [6].
Shortly thereafter, McMillan and Freeman formulated a
comprehensive table and compared clinical presentation,
biochemical ﬁndings, and resolution of the three diﬀerent
types of the milk-alkali syndrome [7]. The subacute form
(Cope’s syndrome) was seen during therapy with calcium
and alkali that had been used intermittently for years. In
contrast to the acute form, there was less rapid improvement
in symptoms and the recovery of renal function was slower.
The chronic form (Burnett’s syndrome) occurred after a
long history of ingestion of large amounts of calcium
and alkali. Presentation of Burnett’s syndrome included
complains of pruritus, diﬀuse musculoskeletal symptoms,
nephrocalcinosis, and band keratopathy with large soft
tissue calcium deposits [5, 8]. Although symptoms usually
improved with the discontinuation of calcium antacids, the
resolution of hypercalcemia was slow, especially in patients2 Case Reports in Medicine
with large soft tissue deposits of calcium. Renal insuﬃciency
often improved but did not resolve completely.
2. Case Presentation
Our patient is a 64-year-old Caucasian male who presented
to the emergency room (ER) with a 2-week complaint
of progressive weakness, dizziness on ambulation, nausea,
and per accompanying family members, a deterioration
in mental status. In the ER, he was hemodynamically
stable, but serum analysis was signiﬁcant for hypercalcemia
of 16.9 with corrected calcium per serum albumin 18.2
(normal 8.4–10.2milligrams per deciliter (mg/dL), formula
forcorrectedserumcalcium=measuredserumcalcium+0.8
∗ (normal albumin – measured patient albumin)), alkalosis
with bicarbonate 34.6 (normal 21.0–31.0millimole per liter
(mmol/L), renal insuﬃciency with BUN 30 (normal 6–
20mg/dL) and creatinine 4.0 (normal 0.5–1.2mg/dL), total
protein 5.8 (normal 6.2–8.2g/dL), albumin 3.0 (normal 3.2–
5.0g/dL), phosphorus 3.1 (normal 2.5–4.6mg/dL), WBC
11.5 (normal 4.5–10.0K/cumm), hemoglobin 14.3 (normal
13.0–17.0g/dL), hematocrit 40.9 (normal 39.0–52.0), and
platelets 341 (normal 140–400K/cumm). Electrocardiogram
(ECG) showed sinus tachycardia at 106 beats per minute,
normal PR, and QRS intervals with QT/QTc 304/400msec.
Arterial blood gas showed alkalemia: pH 7.48 (normal 7.35–
7.45), pCO2 46 (normal 35–45mm/Hg), and O2 saturation
99% (normal 95–98).
With this physical presentation, hypercalcemia with
renal insuﬃciency and alkalosis, he was admitted to acute
medicine ﬂoor. Management included aggressive ﬂuid resus-
citation with normal saline, acute coronary syndrome rule
out,telemetryplacementforcardiacarrhythmiamonitoring,
and workup for the etiology of hypercalcemia. On thorough
history and chart review, the patient admitted to taking large
quantities of over-the-counter calcium supplementation in
the form of TUMS for his chronic acid reﬂux spanning
over 3 decades. Recently, over the past several weeks, due
to worsening reﬂux symptoms, he had increased his daily
TUMS from 5-6 tablets to as much as 20–30 tablets per day.
He had previously been seen in a cardiology clinic (6 months
prior to this presentation) for followup of hypertension
(HTN) and was started on low-dose hydrochlorothiazide
12.5mg per day. He was seen in a pulmonary clinic for
followup of lung nodule (which had previously been worked
up as benign) and in a gastrointestinal clinic 2 months after
cardiology visit and was noted to have serum Ca of 11.6. He
was counseled extensively on stopping over the counter acid
suppressionandgivenprescriptionofomeprazole40mgBID
which he decided not to take.
Etiology workup revealed ionized calcium (iCa) at
8.3 (normal 4.48–5.28mg/dL), intact parathyroid hormone
(iPTH) < 3.0 (normal 10–65pg/mL) indicating non-PTH-
mediated hypercalcemia, parathyroid-hormone-related pep-
tide (PTHrp) at 0, Vit D 1,25 <8 (normal 18–64pg/mL),
and Vit D 25 at 23 (optimum level 25–80ng/mL) ruling
out malignancy and hypervitaminosis. Other causes were
also ruled out with normal serum thyroid studies, serum
protein electrophoresis, chest radiograph, and chest CT
showing no new changes and renal ultrasound being benign.
Gastroenterology and nephrology consults were obtained
to conclude the diagnosis of milk-alkali syndrome and to
formulate multidisciplinary plan. He underwent esopha-
gogastroduodenoscopy(EGD)whichshowedgradeIVreﬂux
esophagitis, distal esophageal stricture, gastritis, and erosive
duodenitis. Pathologic specimen was reported as benign
squamous hyperplasia with negative stain for H. pylori.
Initial ﬂuid resuscitation was supplemented with IV proton
pump inhibitor twice a day and nutrition evaluation and
recommendation; all of which resulted in impressive resolu-
tion of hypercalcemia and restoration of renal functions to
normal thus conﬁrming milk-alkali syndrome. Patient was
later discharged home on omeprazole 40mg twice a day
(BID) and hydrochlorothiazide 12.5mg. As followup, he was
seen in internal medicine clinic 3 months after discharge
with serum Ca of 10.6, albumin 4.3, improvement in reﬂux
symptoms, and baseline functional status.
3. Discussion
Inthemilk-alkalisyndrome,hypercalcemiadevelopsbecause
the input of calcium (dietary intake and intestinal absorp-
tion) exceeds the output (primarily renal excretion). About
4 to 60g/d of calcium carbonate has been reported to
induce the milk-alkali syndrome, indicating that factors
besides calcium intake contribute to the development of the
milk-alkali syndrome [9]. Factors that can increase calcium
input include increased dietary calcium intake, ingestion
of supplemental calcium, enhanced intestinal absorption of
calcium usually resulting from stimulation by vitamin D
that is present in some calcium supplements, and other
dietary factors. Calcium-containing compounds have also
beenshowntodirectlyincreasegastricacidsecretionbystim-
ulating the CaSR (calcium-sensing receptor) when ingested
orally, which in turn increases the availability of free calcium
for absorption [10, 11].
It is likely that bone, the primary repository for calcium,
increases calcium uptake but becomes saturated during high
calcium exposure. The capacity of bone to increase calcium
uptake per unit of bone changes with age as does the extent
of bone remodeling [12, 13]. Randall et al. in 1961 gave
insight into the time course of this syndrome after observing
40 men with peptic ulcer disease who were treated with
milk and either aluminum hydroxide or calcium carbonate
[8]. In the milk–carbonate group (12 grams of calcium per
day), the mean plasma calcium concentration rose within 24
hours from 10mg/dL to 11mg/dL (2.5 to 2.75mmol/L). In
9 of 20 patients treated for one week, the plasma calcium
concentration reached or exceeded 11.3mg/dL (2.8mmol/L)
and, in a few cases, exceeded 12mg/dL (3mmol/L). The
mean plasma bicarbonate concentration rose slightly, but in
three of the 20 patients exceeded 31.5meq/L. The plasma
creatinine concentration rose from 1.2 to 1.4mg/dL (106
to 124mmol/L) on the third day. The plasma phosphate
concentration rose during the ﬁrst few days. One patient
developed the acute milk-alkali syndrome with hypercal-
cemia preceding the development of renal insuﬃciency and
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exposure to excessive calcium and alkali ingestion can cause
marked increases in serum Ca and bicarbonate in rare cases,
mild intermittent hypercalcemia can be seen in a signiﬁcant
number of patients.
Renal vasoconstriction secondary to hypercalcemia leads
to a fall in glomerular ﬁltration rate, and hypercalcemia
directly stimulates tubular hydrogen ion secretion and,
therefore, bicarbonate reabsorption leading to metabolic
alkalosis. The alkalosis helps to maintain hypercalcemia and
volume depletion by enhancing the activity of the CaSR
and by increasing calcium reabsorption in the distal tubule
via the pH-sensitive calcium channel, the transient receptor
potential vanilloid member 5 [TRPV5] [17–19]. Volume
contraction due to vomiting, diuretics, or the natriuretic
eﬀects of hypercalcemia further aggravates hypercalcemia
and alkalosis. Marked hypercalcemia can lead to the patient
presenting with acute toxicity (nausea, vomiting, weakness,
and mental changes with psychosis or depressed sensorium).
After extensive clinical and laboratory evaluation, no evi-
dence of malignant disease or primary hyperparathyroidism
was seen in our patient. No cause of hypercalcemia could be
identiﬁedotherthantheingestionoflargeamountofCaCO3
(calciumcarbonate)withconcurrentuseofthiazide diuretic.
Along with the pathophysiology of hypercalcemia secondary
to large calcium intake and absorption as mentioned above,
thiazide diuretics are known to reduce urinary calcium
excretion and produce mild hypercalcemia [16, 17]. In the
kidney, distal convoluted tubule reabsorbs about 8% of the
ﬁltered Ca load. This occurs via epithelial Ca2+ channels.
In the steady state, the cell must extrude all penetrating
Ca, which occurs via a Ca2+ ATPase and through Na+/Ca2+
exchanger located on the basolateral surface of the cells of
the distal tubule. Thiazides inhibit the Na+/Cl− symport in
the early distal convoluted tubule, thus causing a decrease
in intracellular Na. This, in turn, enhances the activity of
the Na+/Ca2+ exchanger, creating an increased driving for
Ca resorption through the epithelial Ca2+ channels. The ﬁnal
eﬀects increased Ca reabsorption leading to hypercalcemia.
In a novel study, Nijenhuis et al. showed that mice that
lacked active distal Ca2+ reabsorption (TRVP5-knockout)
developed hypercalcemia with hydrochlorothiazide (HCTZ)
treatment and that enhanced passive Ca2+ transport in the
proximal tubule rather than active Ca2+ transport in distal
convolution explains thiazide-induced hypocalciuria [20].
In conclusion, the ingestion of absorbable calcium,
metabolic alkalosis, and concomitant use of thiazide diuretic
can produce severe hypercalcemia which can be potentially
more life threatening than is generally observed with either
agent alone. This must be taken into account while prescrib-
ing thiazide diuretics for hypertension to patient with gastric
reﬂux disease due to the ready availability of nonprescription
medication containing CaCO3.
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